接受那他珠单抗治疗的多发性硬化女性的妊娠决策:II:母体风险
该研究追踪2009至2015年间19个中心的83例接受那他珠单抗治疗的多发性硬化女性共92次妊娠,其中74次活产并随访至少1年,与350次既往报道的妊娠比较。结果显示那他珠单抗组妊娠期间及产后复发率更高(p<0.001),洗脱期越长是妊娠期复发的唯一预测因素(p=0.001),产后早期重启疾病修饰药物可降低产后复发(p=0.021)和残疾进展(p=0.024)。
要点
- 那他珠单抗治疗的多发性硬化女性妊娠期及产后复发率高于干扰素-β治疗或未治疗者(p<0.001)。
- 较长的那他珠单抗洗脱期是妊娠期复发的唯一预测因素(p=0.001)。
- 产后早期重启疾病修饰药物与产后复发减少(p=0.021)及残疾进展减少(p=0.024)相关。
核心结论
- 避免那他珠单抗洗脱联合产后早期重启疾病修饰药物可能是降低母体风险的最佳选择,但需考虑可能的胎儿风险并与母亲讨论,且需进一步研究。
研究设计与样本
- 收集2009至2015年间19个参与中心接受那他珠单抗治疗的多发性硬化患者的全部妊娠数据,与未治疗患者及接受注射免疫调节剂治疗患者的妊娠数据通过两因素重复测量分析进行比较。
- 采用逐步多变量逻辑回归模型评估疾病活动度的预测因素。
- 共追踪83例接受那他珠单抗治疗女性的92次妊娠,其中70例女性的74次妊娠为活产并随访至少1年,与350次既往发表的妊娠数据进行比较。
主要发现
- 那他珠单抗治疗组妊娠期间及产后复发率更高(p<0.001)。
- 多变量分析中,较长的那他珠单抗洗脱期是妊娠期复发发生的唯一预测因素(p=0.001)。
- 产后一年的复发与妊娠期复发(p=0.019)及早期重启疾病修饰药物(p=0.021)相关。
- 16.2%的患者出现残疾进展,早期重启疾病修饰药物可减少残疾进展(p=0.024)。
关键数值与推荐
- 该研究提供IV级证据:在接受那他珠单抗治疗的多发性硬化女性中,妊娠期复发风险高于使用干扰素-β或未治疗者。
临床怎么用
- 作者认为,避免那他珠单抗洗脱联合产后早期重启疾病修饰药物可能是降低母体风险的最佳选择。
- 作者指出该方法必须考虑可能的胎儿风险,需与母亲讨论并进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the risk of disease reactivation during pregnancy after natalizumab suspension in women with multiple sclerosis (MS). METHODS: Data of all pregnancies occurring between 2009 and 2015 in patients with MS treated with natalizumab and referring to 19 participating sites were collected and compared with those of pregnancies in untreated patients and patients treated with injectable immunomodulatory agents through a 2-factor repeated measures analysis. Predictors of disease activity were assessed through stepwise multivariable logistic regression models. RESULTS: A total of 92 pregnancies were tracked in 83 women receiving natalizumab. Among these pregnancies, 74 in 70 women resulted in live births, with a postpartum follow-up of at least 1 year, and were compared with 350 previously published pregnancies. Relapse rate during and after pregnancy was higher in women treated with natalizumab (p < 0.001). In multivariable analysis, longer natalizumab washout period was the only predictor of relapse occurrence during pregnancy (p = 0.001). Relapses in the postpartum year were related to relapses during pregnancy (p = 0.019) and early reintroduction of disease-modifying drugs (DMD; p = 0.021). Disability progression occurred in 16.2% of patients and was reduced by early reintroduction of DMD (p = 0.024). CONCLUSIONS: Taken as a whole, our findings indicate that the combination of avoiding natalizumab washout and the early resumption of DMD after delivery could be the best option in the perspective of maternal risk. This approach must take into account possible fetal risks that need to be discussed with the mother and require further investigation. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that in women with MS, the risk of relapses during pregnancy is higher in those who had been using natalizumab as compared to those who had been using interferon-β or no treatment.
引用
- Portaccio E, Moiola L, Martinelli V, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. Neurology. 2018. PMID: 29438041. doi:10.1212/WNL.0000000000005068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。